Revive Therapeutics (RVVTF) Regulatory Update Archive.
April 12th, 2022 update. Discusses potentially halting the Study early due to positive efficacy based on other clinical outcomes evaluated such as...
Deficiency of Glutathione as the Most Likely Cause of Serious Manifestations and Death in...
American Chemical Society
May 2020.
Higher rates of serious illness and death from coronavirus SARS-CoV-2...
Revive Therapeutics Announces Entry Into Phase III FDA Trial Using Glutathione Boosting Bucillamine.
Revive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial
TORONTO, April...